Table 3 Incidence of chemotherapy-induced thrombocytopenia, by chemotherapy agenta
From: Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
Incidence Proportion (95% CI) | ||||||||
|---|---|---|---|---|---|---|---|---|
All Agents | Carboplatin | Cisplatin | Cyclophosphamide | Fluorouracil | Gemcitabine | Oxaliplatin | Vincristine | |
Evidence of Primary, Secondary, Unspecified Thrombocytopenia and/or Bleeding Events, Receipt of TPOs, or Platelets During Chemotherapy | ||||||||
Course | (n = 215,508) | (n = 60,966) | (n = 22,393) | (n = 83,665) | (n = 42,970) | (n = 6617) | (n = 33,822) | (n = 14,610) |
Overall | 9.7 (9.6–9.8) | 13.2 (12.9–13.5) | 9.9 (9.5–10.3) | 6.1 (5.9–6.3) | 10.9 (10.6–11.2) | 13.5 (12.7–14.3) | 11.4 (11.1–11.8) | 9.6 (9.1–10.1) |
Inpatient | 3.0 (2.9–3.1) | 4.2 (4.1–4.4) | 4.3 (4.1–4.6) | 1.6 (1.5–1.7) | 3.0 (2.9–3.2) | 5.5 (4.9–6.0) | 2.9 (2.7–3.1) | 3.5 (3.2–3.8) |
Outpatient | 6.7 (6.6–6.8) | 9.0 (8.7–9.2) | 5.6 (5.3–5.9) | 4.5 (4.3–4.6) | 7.9 (7.6–8.1) | 8.0 (7.4–8.7) | 8.5 (8.2–8.8) | 6.1 (5.7–6.5) |
All Cycles | (n = 988,195) | (n = 251,611) | (n = 67,304) | (n = 435,897) | (n = 210,734) | (n = 22,310) | (n = 179,105) | (n = 57,387) |
Overall | 2.8 (2.8–2.9) | 4.2 (4.2–4.3) | 4.1 (3.9–4.2) | 1.5 (1.5–1.5) | 3.2 (3.1–3.3) | 5.2 (4.9–5.5) | 3.3 (3.2–3.4) | 3.2 (3.1–3.4) |
Inpatient | 0.7 (0.7–0.7) | 1.1 (1.0–1.1) | 1.5 (1.4–1.6) | 0.3 (0.3–0.3) | 0.6 (0.6–0.7) | 1.7 (1.5–1.9) | 0.6 (0.5–0.6) | 0.9 (0.9–1.0) |
Outpatient | 2.1 (2.1–2.2) | 3.2 (3.1–3.2) | 2.6 (2.4–2.7) | 1.2 (1.1–1.2) | 2.6 (2.5–2.6) | 3.5 (3.2–3.7) | 2.7 (2.7–2.8) | 2.3 (2.2–2.4) |
Cycle 1 | (n = 215,508) | (n = 60,966) | (n = 22,393) | (n = 83,665) | (n = 42,970) | (n = 6617) | (n = 33,822) | (n = 14,610) |
Overall | 2.7 (2.6–2.8) | 3.9 (3.7–4.0) | 3.7 (3.5–4.0) | 1.7 (1.6–1.8) | 2.0 (1.9–2.2) | 7.0 (6.4–7.6) | 1.5 (1.4–1.7) | 4.1 (3.8–4.4) |
Inpatient | 1.0 (1.0–1.0) | 1.4 (1.4–1.5) | 1.7 (1.5–1.9) | 0.6 (0.5–0.6) | 0.7 (0.6–0.8) | 3.0 (2.6–3.5) | 0.5 (0.4–0.6) | 1.5 (1.3–1.7) |
Outpatient | 1.7 (1.7–1.8) | 2.4 (2.3–2.6) | 2.0 (1.9–2.2) | 1.2 (1.1–1.2) | 1.3 (1.2–1.4) | 4.0 (3.5–4.4) | 1.0 (0.9–1.1) | 2.6 (2.3–2.8) |
Cycle 2 | (n = 186,607) | (n = 51,796) | (n = 17,777) | (n = 76,661) | (n = 36,785) | (n = 4255) | (n = 29,562) | (n = 11,552) |
Overall | 2.7 (2.6–2.8) | 3.7 (3.6–3.9) | 3.9 (3.6–4.2) | 1.4 (1.4–1.5) | 2.9 (2.8–3.1) | 5.1 (4.4–5.7) | 2.5 (2.3–2.7) | 3.0 (2.7–3.3) |
Inpatient | 0.8 (0.7–0.8) | 1.0 (0.9–1.1) | 1.4 (1.2–1.6) | 0.3 (0.2–0.3) | 1.0 (0.9–1.1) | 1.4 (1.1–1.8) | 0.7 (0.6–0.8) | 0.8 (0.7–1.0) |
Outpatient | 1.9 (1.9–2.0) | 2.7 (2.6–2.8) | 2.5 (2.3–2.7) | 1.2 (1.1–1.3) | 2.0 (1.8–2.1) | 3.7 (3.1–4.2) | 1.8 (1.6–1.9) | 2.1 (1.9–2.4) |
Cycle 3+ | (n = 586,080) | (n = 138,849) | (n = 27,134) | (n = 275,571) | (n = 130,979) | (n = 11,438) | (n = 115,721) | (n = 31,225) |
Overall | 2.9 (2.9–3.0) | 4.6 (4.5–4.7) | 4.4 (4.2–4.7) | 1.4 (1.4–1.5) | 3.7 (3.6–3.8) | 4.1 (3.8–4.5) | 4.0 (3.9–4.1) | 2.9 (2.7–3.1) |
Inpatient | 0.5 (0.5–0.6) | 0.9 (0.9–1.0) | 1.4 (1.2–1.5) | 0.3 (0.2–0.3) | 0.5 (0.5–0.5) | 1.0 (0.8–1.2) | 0.5 (0.5–0.6) | 0.7 (0.6–0.8) |
Outpatient | 2.4 (2.3–2.4) | 3.7 (3.6–3.8) | 3.0 (2.8–3.3) | 1.2 (1.1–1.2) | 3.1 (3.1–3.2) | 3.1 (2.8–3.4) | 3.5 (3.4–3.6) | 2.2 (2.0–2.3) |